Dexamethasone in hospitalized patients with Covid-19 — preliminary report
<p><strong>BACKGROUND</strong></p> <p>Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.</p> <p><stro...
| Main Authors: | , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
Massachusetts Medical Society
2020
|
| _version_ | 1826293817574162432 |
|---|---|
| author | Horby, P Lim, WS Emberson, J Mafham, M Bell, JL Linsell, L Staplin, N Juszczak, E Haynes, R Landray, M |
| author2 | RECOVERY Collaborative Group |
| author_facet | RECOVERY Collaborative Group Horby, P Lim, WS Emberson, J Mafham, M Bell, JL Linsell, L Staplin, N Juszczak, E Haynes, R Landray, M |
| author_sort | Horby, P |
| collection | OXFORD |
| description | <p><strong>BACKGROUND</strong></p>
<p>Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.</p>
<p><strong>METHODS</strong></p>
<p>In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the preliminary results of this comparison.</p>
<p><strong>RESULTS</strong></p>
<p>A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.91 to 1.55).</p>
<p><strong>CONCLUSIONS</strong></p>
<p>In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936. opens in new tab; ISRCTN number, 50189673. opens in new tab.)</p> |
| first_indexed | 2024-03-07T03:36:01Z |
| format | Journal article |
| id | oxford-uuid:bc4e2f90-b633-4c82-b82b-503e06686b56 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:36:01Z |
| publishDate | 2020 |
| publisher | Massachusetts Medical Society |
| record_format | dspace |
| spelling | oxford-uuid:bc4e2f90-b633-4c82-b82b-503e06686b562022-03-27T05:23:30ZDexamethasone in hospitalized patients with Covid-19 — preliminary reportJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bc4e2f90-b633-4c82-b82b-503e06686b56EnglishSymplectic ElementsMassachusetts Medical Society2020Horby, PLim, WSEmberson, JMafham, MBell, JLLinsell, LStaplin, NJuszczak, EHaynes, RLandray, MRECOVERY Collaborative Group<p><strong>BACKGROUND</strong></p> <p>Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.</p> <p><strong>METHODS</strong></p> <p>In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the preliminary results of this comparison.</p> <p><strong>RESULTS</strong></p> <p>A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.91 to 1.55).</p> <p><strong>CONCLUSIONS</strong></p> <p>In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. (Funded by the Medical Research Council and National Institute for Health Research and others; RECOVERY ClinicalTrials.gov number, NCT04381936. opens in new tab; ISRCTN number, 50189673. opens in new tab.)</p> |
| spellingShingle | Horby, P Lim, WS Emberson, J Mafham, M Bell, JL Linsell, L Staplin, N Juszczak, E Haynes, R Landray, M Dexamethasone in hospitalized patients with Covid-19 — preliminary report |
| title | Dexamethasone in hospitalized patients with Covid-19 — preliminary report |
| title_full | Dexamethasone in hospitalized patients with Covid-19 — preliminary report |
| title_fullStr | Dexamethasone in hospitalized patients with Covid-19 — preliminary report |
| title_full_unstemmed | Dexamethasone in hospitalized patients with Covid-19 — preliminary report |
| title_short | Dexamethasone in hospitalized patients with Covid-19 — preliminary report |
| title_sort | dexamethasone in hospitalized patients with covid 19 preliminary report |
| work_keys_str_mv | AT horbyp dexamethasoneinhospitalizedpatientswithcovid19preliminaryreport AT limws dexamethasoneinhospitalizedpatientswithcovid19preliminaryreport AT embersonj dexamethasoneinhospitalizedpatientswithcovid19preliminaryreport AT mafhamm dexamethasoneinhospitalizedpatientswithcovid19preliminaryreport AT belljl dexamethasoneinhospitalizedpatientswithcovid19preliminaryreport AT linselll dexamethasoneinhospitalizedpatientswithcovid19preliminaryreport AT staplinn dexamethasoneinhospitalizedpatientswithcovid19preliminaryreport AT juszczake dexamethasoneinhospitalizedpatientswithcovid19preliminaryreport AT haynesr dexamethasoneinhospitalizedpatientswithcovid19preliminaryreport AT landraym dexamethasoneinhospitalizedpatientswithcovid19preliminaryreport |